News and Events


  • Public statement regarding recent lawsuit settlement

    Topcon Healthcare is pleased to announce we have reached a positive resolution to a lawsuit with Carl Zeiss Meditec that has been a distraction for over four years. Topcon made a strategic decision to settle ongoing litigation with Zeiss to remove the distraction and allow us to focus on our mission to serve our customers and help improve access and quality of care while reducing the overall cost of care. We are known for quality products and quality people.  We intend to continue delivering value and intelligent solutions to our customers and the healthcare market.  Topcon admitted no wrongdoing in the settlement.  During the (4 years of) litigation almost all of Zeiss’s claims were dismissed or withdrawn.  The final settlement relates to a legacy version of Harmony (which has not been actively licensed by Topcon for several years).  Customers using our current product, Harmony RS, are not affected by the settlement, and none of the devices or software that we are promoting or plan to implement in the future are affected by the conditions in the settlement in any way. 

  • TOPCON selected for the fourth consecutive year as a Digital Transformation Stock (DX stock), and first time chosen for the DX Grand Prix!

    Topcon Corporation (Headquarters: Itabashi, Tokyo; President and CEO: Takashi Eto) has been selected for the DX Grand Prix 2023 in the Digital Transformation Stock (DX Stock) designated by the METI (Ministry of Economy, Trade, and Industry) and the Tokyo Stock Exchange.DX Stocks are selected for each industry category, targeting companies listed on the Tokyo Stock Exchange that have established internal systems to promote DX that contributes to improving corporate value. These companies fundamentally transform their business models based on digital technologies and aim to achieve new growth and enhance their competitiveness through digital transformation.Topcon has been selected for four consecutive years since 2020, and this year was chosen as a “DX Grand Prix company,” an award for being a leading company in the selected stocks.Topcon’s corporate identity is “Topcon contributes to enrich human life by solving the societal challenges within healthcare, agriculture, and infrastructure.” We have been creating new markets by providing DX solutions that transform conventional work processes through digitization, automation, and networking technologies in the global healthcare, agriculture, and infrastructure markets.■ Topcon’s DX Solutions for Solving Societal Challenges in Healthcare, Agriculture, and Infrastructure.[DX Grand Prix 2023 Evaluation Points]Topcon places DX as a driving force for business transformation, and the evaluation points are comprehensive and specific in terms of contributing to corporate value and realization capabilities. The corporate identity states that ” Topcon contributes to enrich human life by solving the societal challenges within healthcare, agriculture, and infrastructure.” and aims to solve these issues with DX solutions. The company actively engages in M&A and partnerships, incorporating advanced technologies and expanding services. They provide integrated solutions that combine technology and services, not just selling products or services, to address the challenges in the target industries. Expectations are high for future developments.Going forward, with a customer-oriented, field-oriented approach and a spirit of challenge, we will continue to strive for “the company that is needed” by stakeholders and promote ESG (environmental, social, and governance) management through our business

  • Topcon Announces eyeRISE 2021 Virtual Symposia & Expo

    Two-Day Special Event Will Showcase The Latest Innovations in Eye CareOAKLAND, NJ – January, 2021 – Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced today that it will host a two-day virtual symposia and expo entitled eyeRISE on February 9-10, 2021.eyeRISE, or Eye Research Innovation Symposia & Expo, is a new, multi-disciplinary virtual congress showcasing the latest innovations in eye care.  It will feature three solutions-focused tracks, delivering clinical and practical education through symposia, roundtable discussions and interactive workshops.The two-day special event will feature more than three dozen globally-renowned speakers representing 17 countries and a range of specialties.  Educational tracks are Building Clinical Confidence which includes topics focused on retina, glaucoma and imaging;  Entering New Markets which addresses the barriers to entering myopia and dry eye management; and Too Many Patients, Not Enough Time highlighting topics such as ocular telehealth and remote diagnostics.“eyeRISE will build on the success of our previous ISSOCT conferences and expand to include all facets of eye care, delivering clinical education for the retina, glaucoma and anterior segment subspecialties. The esteemed lecture panel will present their clinical findings on the latest research topics and innovation in eye care. It should prove to be a highly informative and enlightening meeting for all attendees,”Richard F. Spaide, MD, of Vitreous Retina Macula Consultants of New York, United StatesISSOCT Chairman“We are very excited to announce eyeRISE, a one-of-a-kind, ground-breaking event that will bring together some of the most recognized names in the eye care industry to discuss the latest research and trends in patient care and practice management.  In the absence of live meetings, eyeRISE provides an engaging, interactive virtual platform and offers education for a wide range of disciplines.  It features solution-focused tracks for real world clinical and business management applications.  eyeRISE is the culmination of Topcon’s unwavering commitment to support continued innovation in eye care,” stated Carolyn Evangelista, Global Director of Medical Affairs for Topcon Healthcare.“Having the opportunity to network with colleagues and learn about the latest trends and technologies in eye care is critical for today’s practitioners, particularly in light of the global pandemic. eyeRISE provides practitioners with a unique opportunity to interact with the faculty and each other and gain practical tips and clinical insights.  Given the challenges facing today’s eye care practitioners, eyeRISE represents a wonderful learning opportunity for all clinicians,” summarized faculty member Mingguang He, MD, PhD, Professor at the University of Melbourne, Australia.For more information on eyeRISE or to register for the event, please visit Topcon HealthcareTopcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever- changing landscape of the healthcare industry, we offer the latest integrated solutions including advanced multimodal imaging, vendor-neutral data management, safe distancing and ground-breaking remote diagnostic technology.A globally-oriented business, Topcon is focused on developing solutions towards solving societal challenges in the mega-domains of healthcare, agriculture, and infrastructure. In healthcare, these challenges include increasing eye disease, rising medical costs, access to healthcare and physician shortages. By investing in value-driven innovations, Topcon works to enable people to enjoy good health and a high quality of life.



  • Notice of Changes of President and CEO (Replacement of President)

    January 30, 2023Topcon Corporation (TSE: 7732) hereby announces that the change of President and CEO was resolved at a meeting of the board of directors held today. The appointments will take effect on April 1, 2023.Change of President and CEO(effective April 1, 2023)NameNew PositionCurrent PositionSatoshi HiranoRepresentative Director,ChairmanRepresentative Director,President & CEOTakashi EtoRepresentative Director,President & CEORepresentative Director,Executive Vice PresidentGeneral Manager, Quality Assurance Div.Takashi EtoTopcon Corporation, the parent company of all Topcon Healthcare companies, announced changes in their president and CEO position that will be effective with the new fiscal year. Takashi Eto will assume the position of Representative Director,  President and CEO, effective April 1, 2023. Current Topcon Corporation President and CEO Satoshi Hirano has served in the role since 2013 and will continue to contribute to the development of Topcon as Chairman of the Board, assisting and advising the new president.Read the news on the Topcon Corporation Website : link

  • Topcon Introduces NW500 Non-Mydriatic Retinal Camera

    TOKYO, JAPAN, OCTOBER 2022 – Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, is pleased to announce that it has launched the NW500, its new fully-automatic, non-mydriatic retinal camera that delivers reliable, sharp-quality imaging with enhanced capability.The NW500 offers innovative slit scan illumination and a rolling shutter mechanism, which helps to overcome one of the known causes of poorly graded images in its ability to effectively image smaller pupils, from 2.00mm or more*. A 12-megapixel sensor delivers excellent quality colour fundus images for clear review and analysis.The NW500 contributes to a streamlined workflow and enhanced patient experience by offering the ability to acquire retinal images in a lighted setting without the need to dilate patients. The NW500 offers excellent quality colour fundus images across the traditional 3 fixation points (Disc, Centre, and Macula), as well as the 9 fixation positions for peripheral photography.Touch-screen operation offers rapid, simple capture with just one touch. Fully-automated operation gives clinicians the flexibility to delegate screening to non-clinical staff. The improved processing speed** means it takes less time to capture images and gives operators the ability to increase patient throughput. A variety of connectivity options are available to suit the needs of clinical and screening businesses.“The NW500 reflects Topcon’s commitment to continuous innovation in pursuit of technology that helps to improve the quality-of-care patients receive and make care more efficient and accessible,” says Senior Director of Product Management, Tobias Kurzke. “Combined, the innovative slit scan technology and 12-megapixel camera offer clinicians fast, sharp quality imaging with less failure and retakes, making the process of acquiring fundus images faster and more reliable than before. The added benefit of enhancing the patient experience through faster screening times and the absence of the need for dilation will give clinicians and large volume wellness screening settings a competitive advantage.”Find out more about NW500* Confirmed with model eye** As compared to the Topcon non-mydriatic retinal camera TRC-NW400Note: The information contained on this website is intended for healthcare professionals. Not all products, services or offers are approved or offered in every market, and products vary from one country to another. Contact your local distributor for country-specific information and availability.

  • The Market Leader in OCT & Data Management Joins Forces with AI Expert to Provide Improved Clinical Care

    Topcon Healthcare of Oakland, NJ, a leading provider of medical devices and software solutions for the global eye care community, announced today that it will partner with RetInSight GmbH, a developer of retina AI solutions based in Vienna, Austria. The two companies aim to develop a seamless interface between RetInSight’s AI-assisted retinal biomarker applications and Topcon’s market-leading¹ OCT devices and cloud-based data management solution, Harmony.RetInSight’s novel, proprietary algorithms aim to support clinicians in the detection, quantification, and monitoring of key retinal biomarkers including retinal fluid and geographic atrophy lesions. With this collaboration, Topcon and RetInSight hope to extend retinal fluid detection and monitoring to primary eye care providers, facilitating comanagement of patients. In parallel, the two companies intend to develop and deploy automated, OCT-based screening and monitoring applications of geographic atrophy (GA), the leading cause for severe and irreversible visual loss. The availability of RetInSight’s novel OCT-based biomarker algorithms on Topcon’s solutions further augments the clinical utility and versatility of the workflow efficient Maestro2 Robotic OCT and the Triton Swept Source OCT. The cloud based Harmony data management system is known for its seamless connection to hundreds of ophthalmic devices across multiple practice locations to enable analysis of relevant clinical data in a single, secure platform. Harmony streamlines office workflow, allows for detailed analysis of clinical data, and integrates seamlessly with EMR software and will facilitate the deployment of RetInSight’s AI solutions without compromise of clinical efficiency.“Combining Topcon’s high quality imaging and data management with RetInSight’s novel AI application will lead to improved clinical decision making and efficient disease management. We are very pleased to add this powerful module to our already robust Harmony clinical data management solution and to our world-leading OCT’s,” said Tobias Kurzke, Director of Product Management for Topcon Healthcare.“RetInSight´s partnership with Topcon will facilitate access of AI-based solutions to primary eye care providers, elevating the standard of care by enabling early detection and accurate referrals to advanced eye care specialists for timely treatment of the major retinal diseases. RetInSight’s Clinical Decision Support System and Topcon’s global OCT and PACs footprint offers an unprecedented opportunity for co-management of patients with retinal diseases,” summarized Corinna zur Bonsen-Thomas, Chief Executive Officer of RetInSight.About RetInSight GmbHRetInSight is a digital health company developing transformational retinal AI solutions to improve patient outcomes, increase clinical efficiency and reduce healthcare costs. They empower eye care providers and professionals, academic institutions, and the eye care industry to reimagine clinical care with their extensive artificial intelligence solutions. RetInSight helps its partners leverage data to provide novel insights in unmet diagnostic needs associated with diseases that manifest in the retina. They have developed a comprehensive library of validated AI-algorithms for retinal biomarkers in systemic and retinal diseases, trained on extensive and continuously growing databases. Bringing together the most advanced technologies in computer science and state-of-the-art clinical expertise as well as medical science, they are set on shaping the future of digital precision medicine.1. As reported by Market Scope’s 2020 Ophthalmic Diagnostic Equipment Market Report.【Press release information in US】




Upcoming Events